| The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients (NCT00001030) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients (NCT00000821) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients (NCT00000861) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) (NCT00027352) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| An HIV Vaccine Preparedness Study (NCT00000915) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine (NCT00000720) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease (NCT00000696) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus (NCT02950688) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment (NCT00011128) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis (NCT00004736) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women (NCT01443117) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052 (NCT00091416) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules (NCT00001076) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults (NCT00073216) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care (NCT00028327) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults (NCT00111605) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads (NCT00036465) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members (NCT00000703) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Use of a Test That Evaluates How the Body Handles Insulin and Glucose (NCT00027092) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers (NCT00000871) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HIV Prevention Counseling for Men Who Have Sex With Men (NCT00000931) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113) (NCT00000804) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis (NCT00000639) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs (NCT00050921) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine (NCT00000635) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC (NCT00000753) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis (NCT00000708) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens (NCT00001091) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy (NCT00000969) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells (NCT00000667) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers (NCT00098163) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART) (NCT00000922) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals (NCT00000736) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol (NCT00000799) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults (NCT00100581) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir (NCT00000898) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults. (NCT00001044) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals (NCT00000633) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections (NCT00000858) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis (NCT00000794) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3 (NCT00000756) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines (NCT00056745) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo) (NCT00000765) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection. (NCT00000764) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients (NCT00000906) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir (NCT00001133) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma (NCT00000660) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Immune System Activity in Healthy Adults (NCT00014053) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease (NCT00000881) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation (NCT00036452) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| APSV in Vaccinia Naive Adults (NCT00050518) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| SCH708980 With and Without AmBisome for Visceral Leishmaniasis (NCT01437020) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia (NCT00000705) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS (NCT00000975) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients (NCT00001084) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy (NCT00000842) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP (NCT00000700) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa (NCT01927835) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS (NCT00000717) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient (NCT00000661) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants (NCT00000961) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study (NCT01376765) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC (NCT00000735) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A "Pre-Enrollment" Protocol for HIV-Infected Adolescents (NCT00000780) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection (NCT00001036) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood (NCT00000916) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS (NCT00000715) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of Anti-HIV Therapy Intensification (NCT00034086) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU (NCT00000654) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3 (NCT00000754) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pilot Study Freeze and Transport Immune Cells (NCT00138268) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure (NCT00000691) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children (NCT00001111) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs (NCT00037063) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines (NCT00008853) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS (NCT00001014) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy (NCT00102206) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients (NCT00036478) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children (NCT00000876) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals (NCT00001080) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection (NCT00006339) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease (NCT00000814) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns (NCT00000642) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs (NCT00013871) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection (NCT00006443) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir (NCT00000970) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women (NCT00000758) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole (NCT00001027) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel (NCT00028132) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy. (NCT00000678) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems (NCT00001015) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children (NCT00001118) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules (NCT00000957) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of Women Who Have AIDS (NCT00001050) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers. (NCT00000846) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals (NCT00001042) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pharma-Pen (Formerly Innoject) Auto-injectory TIV (NCT00335855) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens (NCT00053443) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen (NCT00000782) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients. (NCT00000629) | National Institute of Allergy and Infectious Diseases (NIAID) | |